PLX3397
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
May 25, 2012 → Mar 11, 2013
NCT ID
NCT01499043About PLX3397
PLX3397 is a phase 2 stage product being developed by Daiichi Sankyo for Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01499043. Target conditions include Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Prostate Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02975700 | Pre-clinical | Completed |
| NCT01499043 | Phase 2 | Terminated |
| NCT01349036 | Phase 2 | Terminated |
| NCT01217229 | Phase 2 | Completed |
| NCT01004861 | Phase 1 | Completed |
Competing Products
20 competing products in Prostate Cancer